Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
December 31 2018 - 10:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
Commission File Number
|
001-35050
|
Endocyte, Inc.
(Exact name of registrant as specified in its charter)
3000 Kent Avenue, Suite A1-100,
West Lafayette, Indiana 47906
765-463-7175
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
x
|
|
|
|
|
|
Rule 12g-4(a)(2)
|
o
|
|
|
|
|
|
Rule 12h-3(b)(1)(i)
|
x
|
|
|
|
|
|
Rule 12h-3(b)(1)(ii)
|
o
|
|
|
|
|
|
Rule 15d-6
|
o
|
|
|
|
|
|
Rule 15d-22(b)
|
o
|
|
|
|
|
Approximate number of holders of record as of the certification or notice date: One
Pursuant to the requirements of the Securities Exchange Act of 1934, Endocyte, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date:
|
December 31, 2018
|
|
|
Endocyte, Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael T. Andriole
|
|
|
|
|
Michael T. Andriole
|
|
|
|
|
Chief Financial Officer
|
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2023 to Aug 2024